Advertisement
Home »

Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.

Aug 07, 2023

ABOUT THE EXPERTS

  • Pauline Corbaux

    EA UCBL/HCL 3738, Centre pour l’lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France; Medical Oncology, Institut de Cancérologie et d’Hématologie Universitaire de Saint-Étienne (ICHUSE), Centre Hospitalier Universitaire de Saint-Etienne, France.

    Benoit You

    EA UCBL/HCL 3738, Centre pour l’lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, GINECO, GINEGEPS, Lyon, France. Electronic address: benoit.you@chu-lyon.fr.

    Rosalind M Glasspool

    Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK.

    Nozomu Yanaihara

    Department of Obstetrics and Gynecologye, The Jikei University School of Medicine, Tokyo, Japan.

    Anna V Tinker

    Medical Oncology, BC Cancer – Vancouver, Vancouver, Canada.

    Kristina Lindemann

    Department of Gynaecological Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

    Isabelle L Ray-Coquard

    Medical Oncology Department, Centre Léon Bérard, GINECO, Lyon, France.

    Mansoor R Mirza

    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Clinical Trial Unit, Nordic Society of Gynaecological Oncology, Copenhagen, Denmark.

    Fabien Subtil

    Department of Biostatistics, Hospices Civils de Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, CNRS UMR 5558, Claude Bernard University Lyon 1, Lyon, France.

    Olivier Colomban

    EA UCBL/HCL 3738, Centre pour l’lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France.

    Julien Péron

    Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, GINECO, GINEGEPS, Lyon, France; Department of Biostatistics, Hospices Civils de Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, CNRS UMR 5558, Claude Bernard University Lyon 1, Lyon, France.

    Eleni Karamouza

    Institut Gustave Roussy, Office of Biostatistics and Epidemiology, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France.

    Iain McNeish

    Department of Surgery and Cancer, Imperial College London, London, UK.

    Caroline Kelly

    Cancer Research UK Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

    Tatsuo Kagimura

    Foundation for Biomedical Research and Innovation at Kobe, Translational Research Center for Medical Innovation, Kobe, Japan.

    Stephen Welch

    Department of Oncology, London Health Sciences Centre, London, Ontario, Canada.

    Liz-Anne Lewsley

    Cancer Research UK Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

    Xavier Paoletti

    Institut Curie, St Cloud, France.

    Adrian Cook

    Medical Research Council Clinical Trials Unit, University College London, London, UK.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement